AKRO - Akero Therapeutics, Inc.

QQQ $ 442.76 $ -0.65 (-0.15 %)

DIA $ 394.55 $ -1.83 (-0.46 %)

SPY $ 520.64 $ -1.95 (-0.37 %)

TLT $ 90.56 $ 0.22 (0.24 %)

GLD $ 216.26 $ -0.92 (-0.42 %)

Previous Close

$ 19.65

Open

$ 20.16

Bid

$ 20.62 x 100

Ask

$ 20.92 x 100

Day's Range

$ 20.07 - $ 21.46

52 Week Range

$ 11.25 - $ 58.38

Volume

567,401

Average Volume

Market Cap

1.17B

Beta (5Y Monthly)

$ 0.31

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-10-2024	03-31-2024	10-Q
2	02-29-2024	12-31-2023	10-K
3	11-13-2023	09-30-2023	10-Q
4	08-11-2023	06-30-2023	10-Q
5	05-15-2023	03-31-2023	10-Q
6	03-17-2023	12-31-2022	10-K
7	11-04-2022	09-30-2022	10-Q
8	08-04-2022	06-30-2022	10-Q
9	05-06-2022	03-31-2022	10-Q
10	02-25-2022	12-31-2021	10-K
11	11-12-2021	09-30-2021	10-Q
12	08-13-2021	06-30-2021	10-Q
13	05-13-2021	03-31-2021	10-Q
14	03-16-2021	12-31-2020	10-K
15	11-12-2020	09-30-2020	10-Q
16	08-12-2020	06-30-2020	10-Q
17	05-13-2020	03-31-2020	10-Q
18	03-16-2020	12-31-2019	10-K
19	11-12-2019	09-30-2019	10-Q
20	08-12-2019	06-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Canaccord Genuity Maintains Buy on Akero T...
05/13/2024 16:35:51

Canaccord Genuity analyst Edward Nash maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and lowers the price target from...

HC Wainwright & Co. Reiterates Buy on Aker...
05/13/2024 10:44:16

HC Wainwright & Co. analyst Ed Arce reiterates Akero Therapeutics (NASDAQ:AKRO) with a Buy and maintains $50 price target.

Akero Therapeutics Q1 EPS $(0.90) Beats $(...
05/10/2024 11:15:12

Akero Therapeutics (NASDAQ:AKRO) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(...

B of A Securities Reinstates Neutral on Ak...
04/22/2024 10:21:38

B of A Securities analyst Alexandria Hammond reinstates Akero Therapeutics (NASDAQ:AKRO) with a Neutral and announces $30 pr...

Akero Therapeutics Publishes Phase 2b SYMM...
03/07/2024 21:02:33

As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable ...

Akero Therapeutics Prices Public Offering ...
03/06/2024 07:16:58

The comnay announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offeri...

Akero Therapeutics shares are trading lowe...
03/05/2024 17:25:29

UBS Maintains Buy on Akero Therapeutics, R...
03/05/2024 14:43:55

UBS analyst Eliana Merle maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target from $39 to $42.

HC Wainwright & Co. Maintains Buy on Akero...
03/05/2024 11:46:20

HC Wainwright & Co. analyst Ed Arce maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target fr...

Akero Therapeutics Begins Public Offering ...
03/04/2024 21:23:10

All of the shares in the proposed offering are being offered by Akero Therapeutics. In addition, Akero Therapeutics intends to ...

why-bitdeer-technologies-shares-are-trading-higher-by-10-here-are-other-stocks-moving-in-mondays-mid-day-session

Why Bitdeer Technologies Shares Are Tradin...
03/04/2024 18:29:18

Shares of Bitdeer Technologies Group (NASDAQ: BTDR) rose sharply during Monday’s session after the company reported prelimina...

10-health-care-stocks-whale-activity-in-todays-session

10 Health Care Stocks Whale Activity In To...
03/04/2024 17:35:23

akero-therapeutics-stock-is-soaring-monday---heres-why

Akero Therapeutics' Stock Is Soaring Monda...
03/04/2024 16:28:00

Akero Therapeutics success in HARMONY Phase 2b study for efruxifermin. EFX demonstrated sustained efficacy and well-tolerance, ...

Market-Moving News for March 4th
03/04/2024 13:47:02

AKRO: 99% | Akero Therapeutics Released Preliminary Topline Week 96 Results From HARMONY Phase 2B Study Of Efruxifermin For Pre...

Akero Therapeutics Released Preliminary To...
03/04/2024 11:06:29

50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of M...

Super Micro Computer, Deckers Outdoor And ...
03/04/2024 10:01:11

U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 50 points on Monday. Shares of Super ...

HC Wainwright & Co. Maintains Buy on Akero...
03/01/2024 18:59:51

HC Wainwright & Co. analyst Ed Arce maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target fr...

10 Health Care Stocks Whale Activity In To...
02/29/2024 17:35:24

Akero Therapeutics To Present Topline Week...
02/29/2024 13:46:29

Akero Therapeutics: Q4 Earnings Insights
02/29/2024 12:55:11